Editorial
Split Viewer
Korean J Hematol 2011; 46(3):
Published online September 30, 2011
https://doi.org/10.5045/kjh.2011.46.3.145
© The Korean Society of Hematology
Low-grade lymphoma: Beyond fludarabine-single therapy
Division of Hematology and Oncology, Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
REFERENCES
- Horning, SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol, 1993;20;75-88.
- McLaughlin, P, Hagemeister, FB, Romaguera, JE, et al. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol, 1996;14;1262-1268.
- Zinzani, PL, Bendandi, M, Magagnoli, M, Gherlinzoni, F, Merla, E, Tura, S. Fludarabine-mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin's lymphoma. Ann Oncol, 1997;8;379-383.
- Lazzarino, M, Orlandi, E, Montillo, M, et al. Fludarabine, cyclophosphamide, and dexamethasone (FluCyD) combination is effective in pretreated low-grade non-Hodgkin's lymphoma. Ann Oncol, 1999;10;59-64.
- Zinzani, PL, Magagnoli, M, Bendandi, M, et al. Efficacy of fludarabine and mitoxantrone (FN) combination regimen in untreated indolent non-Hodgkin's lymphomas. Ann Oncol, 2000;11;363-365.
- Ferrario, A, Merli, F, Luminari, S, et al. Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL). Ann Hematol, 2011;90;323-330.
- Eichhorst, BF, Busch, R, Hopfinger, G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood, 2006;107;885-891.
- van Oers, MH, Klasa, R, Marcus, RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood, 2006;108;3295-3301.
- Dreyling, M, Forstpointner, R, Gramatzki, M, et al. Rituximab maintenance improves progression-free and overall survival rates after combined immuno-chemotherapy (R-FCM) in patients with relapsed follicular and mantle cell lymphoma: final results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol, 2006;24;7502.
- Fowler, N, Kahl, BS, Lee, P, et al. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study. J Clin Oncol, 2011;29;3389-3395.
PDF
Standard view
Export citation
Share Article
Editorial
Korean J Hematol 2011; 46(3): 145-147
Published online September 30, 2011 https://doi.org/10.5045/kjh.2011.46.3.145
Copyright © The Korean Society of Hematology.
Low-grade lymphoma: Beyond fludarabine-single therapy
Eunkyung Park, M.D. Ph.D.
Division of Hematology and Oncology, Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
- Horning, SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol, 1993;20;75-88.
- McLaughlin, P, Hagemeister, FB, Romaguera, JE, et al. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol, 1996;14;1262-1268.
- Zinzani, PL, Bendandi, M, Magagnoli, M, Gherlinzoni, F, Merla, E, Tura, S. Fludarabine-mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin's lymphoma. Ann Oncol, 1997;8;379-383.
- Lazzarino, M, Orlandi, E, Montillo, M, et al. Fludarabine, cyclophosphamide, and dexamethasone (FluCyD) combination is effective in pretreated low-grade non-Hodgkin's lymphoma. Ann Oncol, 1999;10;59-64.
- Zinzani, PL, Magagnoli, M, Bendandi, M, et al. Efficacy of fludarabine and mitoxantrone (FN) combination regimen in untreated indolent non-Hodgkin's lymphomas. Ann Oncol, 2000;11;363-365.
- Ferrario, A, Merli, F, Luminari, S, et al. Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL). Ann Hematol, 2011;90;323-330.
- Eichhorst, BF, Busch, R, Hopfinger, G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood, 2006;107;885-891.
- van Oers, MH, Klasa, R, Marcus, RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood, 2006;108;3295-3301.
- Dreyling, M, Forstpointner, R, Gramatzki, M, et al. Rituximab maintenance improves progression-free and overall survival rates after combined immuno-chemotherapy (R-FCM) in patients with relapsed follicular and mantle cell lymphoma: final results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol, 2006;24;7502.
- Fowler, N, Kahl, BS, Lee, P, et al. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study. J Clin Oncol, 2011;29;3389-3395.
Previous Article
